Editorials

Donaldson Company filed its fiscal 2026 10-K on September 25, 2026, documenting a year of restrained earnings growth and modest operating leverage. The company generated $2.886 billion in revenue (up 5.3% year-over-year) with operating income of $599.9 million and net income of $453.8 million. These results paint a picture of a stable but uninspiring performer in global filtration—one that has returned capital aggressively to shareholders while taking on significant M&A debt, leaving value investors with a complex calculus.

Let's ground ourselves in the fundamentals. Donaldson generated gross profit of $1.346 billion on revenue of $2.886 billion, yielding a gross margin of 46.6%. This is respectable and stable—a testament to the company's mix of OEM and high-margin aftermarket businesses. Operating income of $599.9 million translates to an operating margin of 20.8%, well above many industrial peers, yet this number masks a concerning headwind: the company's operating margins remain relatively stagnant despite revenue growth.

The real story lies in cash. Operating cash flow reached $493.7 million in fiscal 2026. After capital expenditures of $67.4 million, free cash flow stood at approximately $426.3 million—up 25.4% year-over-year according to the company's metrics. This is genuine cash generation, not accounting fiction. Yet the company returned $252.4 million to shareholders ($141.2 million in dividends and $111.2 million in share repurchases), leaving a modest retained cushion.

Donaldson's business is bifurcated into three segments, and the health check is clear:

Mobile Solutions (59.9% of revenue at $1.730 billion) generated operating income of $404.5 million, representing a segment operating margin of 23.4%. This is the crown jewel—the OEM and aftermarket filtration business for construction, mining, agriculture, and transportation equipment. The strength here is real and defensible.

Industrial Solutions (5.7% of revenue at $165.4 million) contributed $198.8 million in operating income, a segment margin of 120.2%. This segment includes power generation, aerospace, and defense—higher-margin but smaller-scale businesses. The extraordinarily high margin here suggests either extremely tight cost discipline or substantial accounting allocation of corporate overhead to other segments.

Life Sciences (9.3% of revenue at $269 million) posted operating losses of $10.4 million. This nascent segment, built through recent acquisitions (Isolere Bio, UTEC, Solaris, Purilogics), is not yet profitable at scale. It consumed capital and resources without contributing operating earnings in FY 2026—a reminder that bioprocessing integration is unfinished business.

The math is sobering: if we net out Life Sciences' $10.4 million operating loss, the core filtration business (Mobile + Industrial) generates $603.3 million on $1.895 billion in revenue—a 31.8% operating margin. This is a genuinely profitable core business. Life Sciences is the drag, albeit one with asymmetric upside if execution improves.

Here is where the story becomes complex. During fiscal 2026, Donaldson incurred a staggering $822.6 million in acquisition spending (net of cash acquired), while taking on $858.9 million in new long-term debt issuance. The balance sheet reflects this shift: long-term debt stands at $1.283 billion as of July 31, 2026.

The company is financing a bioprocessing strategy bet with leverage, not retained earnings. This is not inherently reckless—bioprocessing is a high-margin, recurring-revenue business with genuine secular tailwinds from cell and gene therapy adoption. Yet it represents a material pivot in capital allocation and financial risk.

What is notably absent is a clear articulation of returns on this M&A capital. Donaldson's management has not disclosed expected ROIC or synergy targets for recent acquisitions. This opacity is troubling for value investors accustomed to disciplined capital allocation frameworks.

As of the filing date, Donaldson traded at approximately $94.24 per share, yielding these metrics:

• P/E multiple: 22.7×
• Price-to-Free-Cash-Flow: 23.8×
• Price-to-Sales: 2.61×
• Enterprise Value / EBIT: 18.7×
• Earnings yield: 4.4% (or inverse: 22.7× earnings)
• Free cash flow yield: 4.2%

For context, the dividend yield is 1.37%, implying total shareholder yield (dividend + buyback) of roughly 2.5–3% before multiple expansion or growth.

These multiples are not cheap. The market is pricing in the Mobile Solutions quality and stable cash generation, but also discounting significant execution risk on Life Sciences integration and uncertainty around the sustainability of bioprocessing margins once these acquisitions are fully absorbed and competitive pressures materialize.

First: Is the Mobile Solutions core business sustainable? At 23.4% operating margins and fueled by cyclical OEM capital expenditure and robust aftermarket replacement demand, Mobile Solutions represents genuine durable competitive advantage. The PowerCore and Ultra-Web filter technologies are difficult to replicate. Yet this business faces inevitable cyclical headwinds—construction and mining equipment replacement rates correlate with capex cycles. When the next industrial downturn arrives, this margin base will contract.

Second: Can Life Sciences turnaround justify the $822.6 million acquisition spend? Bioprocessing is attractive, but integrating multiple small acquisitions and scaling them to profitability is execution-intensive. At current run rates (losing $10.4 million in FY 2026 despite $269 million in revenue), Life Sciences is burning shareholder capital. The company must demonstrate clear EBITDA inflection within 18–24 months. Absent that, this capital was deployed at poor returns.

Third: Is the capital structure appropriate? $1.283 billion in long-term debt on $453.8 million in net income implies a net leverage multiple of ~2.8× EBITDA (estimated at $706 million including D&A). This is not distress-level leverage, but it is elevated for a cyclical business. If the Mobile cycle turns sharply downward, or Life Sciences proves terminal, Donaldson has limited financial flexibility.

Donaldson is not a broken business. The core filtration franchise is robust, cash-generative, and defensible. Management has a coherent long-term strategy—extending filtration into higher-margin, recurring-revenue domains like bioprocessing and vehicle electrification. The balance sheet, while leveraged, is not distressed.

But here's the rub: the company is trading at 22.7× earnings for single-digit revenue growth, modest operating leverage, cyclical exposure, and a bioprocessing bet that remains unproven. The free cash flow yield of 4.2% is available from many lower-risk alternatives. The dividend, while growing, is modest and offers limited margin of safety against a downturn.

Value investors should ask themselves: Is Donaldson worth owning at these multiples? The answer depends entirely on confidence in management's ability to:

1. Maintain Mobile Solutions margins above 20% through a full cycle
2. Scale Life Sciences to 15%+ operating margins within 24 months
3. Service the elevated debt load without constraining strategic flexibility

If you believe management will achieve all three, the stock is reasonably priced. If you harbor doubts on any dimension, current valuation offers insufficient margin of safety.